SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious diseases, today announced that chairman and chief executive officer, Dr. Keting Chu, M.D., Ph.D., will present at the 2nd Global IR@JPM Conference on Thursday, January 20, 2022 in the biotech track to be held 7:30 – 9:30 p.m. ET.
Dr. Chu will provide an overview of the company, including BlueJay’s two therapeutic approaches with potential high rate of functional cure for HBV infections — its best-in-class anti-HBsAg monoclonal antibody approach and novel, first-in-class HBsAg inhibitor program — its preeminent management team with a proven track record in anti-infectives, strong patent position and backing by top healthcare investors.
To access the live webcast, please visit https://www.eventbrite.com/e/2022-global-ir-jpm-virtual-demo-day-tickets-220953005387.
About BlueJay Therapeutics
BlueJay Therapeutics is a private biopharmaceutical company focused on cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. BlueJay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. For more information on BlueJay, please visit the company’s website at www.bluejaytx.com.
Contact:
Alexandra Santos
asantos@wheelhouselsa.com
- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov.…
- Attruby is the first and only approved product with aspecifying near-complete stabilization…
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape -…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…